APPENDIX I

Table 11 Data on the source of *C. albicans* evaluated and respective number of clones and clusters as per the source of collection.

Patient No.	Patient's Code	Number of strains	Number of clones	Number of cluster	Cluster No.
1	A001A	1	-	-	-
2	A001B	3	3	2	6, 7
3	A002B	12	11	3	7, 12, 13
4	A003A	5	5	1	7
5	A003B	3	3	1	5
6	A004A	2	2	1	4
7	A005A	1	-	-	-
8	A006A	4	4	1	19
9	A007A	3	3	1	10
10	A007B	8	8	3	10, 11, 19
11	A008A	1	-	-	-
12	A008B	2	2	1	4
13	A010A	1	-	1	-
14	A012A	3	3	2	11, 20
15	A013A	2	2	1	3
16	A014A	3	3	2	8, 20
17	A016A	2	2	1	20
18	A016B	5	5	5	5, 20, uncluster 3 strains
19	A017B	3	3	1	20
20	A018A	1	-	-	-
21	A018B	4	4	3	3, 10, uncluster 1 strain
22	A019B	15	15	3	2, 11, 14
23	A020B	3	2	1	17
24	A021A	1	-	-	-
25	A025A	1	-	-	-
26	A025B	2	2	1	5
27	A026B	3	3	1	8
28	A027A	3	3	2	8, 18
39	A027B	2	1	1	8
30	A028A	1	-	-	-
31	A030B	3	3	2	5, 8
32	A036B	7	7	2	15, 16
33	A039B	5	3	2	8, 16
34	A052B	9	9	3	8, 13, 16
35	A053B	3	3	2	13, 16

Table 1 (cont.)

Patient No.	Patient's Code	Number of strains	Number of clones	Number of cluster	Cluster No.
36	A059B	14	6	3	16, 17, uncluster 1 strain
37	A081B	10	5	1	6
38	A082B	5	4	1	6
39	A083B	14	9	2	6, 18
40	A020C	12	12	1	9
41	A022C	7	7	2	1, 11
Total	41	189	157		

Note: More than two strains were isolated from 33 of 41 and one strain only from 8 individuals.

Table 12 Patient code details and the numbers of *C. albicans* strain (s) isolated from HIV-free subjects.

Patient number	Patient Code	No. of strains	No. of clones	No. of cluster
1	N001	1	-	-
2	N003	1	-	-
3	N005	1	-	-
4	N007	1	-	-
5	N008	1	-	-
6	C010	12	10	4

APPENDIX II

GES reagent

The solution was prepared by dissolving 30 g guadinidium thiocyanate at 65°C in 20 ml 0.5 M EDTA at pH 8.0 and than 2.5 ml of 10% w/vol. sarkosyl added, finally made up to 50 ml with distilled water.

Ribonuclease A (RNase A)

The solution was prepared bu dissolving 5 mg of RNase A (Sigma) in 1 ml of 10 mM Tris-HCl, 15 mM NaCl to provide a concentration of 5 mg/ml. The solution was heated to 100°C in a water both for 15 minutes, allowed to cool slowly to room temperature and stored in aliqouts at -20°C.

APPENDIX III



Figure 13 Dendrogram of 112 *C. albicans* strains from HIV-infected individuals. The genotypes of these strains were subsequently compared with the phenotypes derived from the API assessment.

APPENDIX IV

Table 13 Details of clusters with genotypes, biotypes and ketoconazole susceptibility test of *C. albicans* strains studied.

Cluster	strain	Biotype	Ketoconazole susceptibility
1	A007/1A	A14S	.015
	A007/2B	A7S	.015
	A006/1A	D1S	4.0
	A006/2A	B4S	-
	A006/4A	D1S	-
	A006/7A	B22S	-
2	A014/1A	-	-
	A017/3B	A13S	.125
	A016/5B	A25S	.0075
	A016/1A	D1R	.06
	A014/2A	-	-
	A017/2B	A23S	.06
	A016/3A	-	-
	A012/1A	C1S	.03
	A017/5B	A13S	.125
	A012/4A	A1S	.06
3	A001/3B	A13S	.03
	A001/1B	A1S	.03
	A002/2B	C13S	-
4	A036/5B	A27R	4.0
	A036/1B	G5R	.025
	A019/8B	-	-
	A019/4B	A6R	.06
	A019/1B	A1S	.06

Table 13 (cont.)

Cluster	strain	Biotype	Ketoconazole susceptibility
	A020/2B	A1S	.031
	A020/5B	A1S	.031
	A020/3B	A1S	.015
	A059/5B	G1S	.031
5	A026/1B	A1S	.015
	A026/2B	A1S	.015
	A026/3B	B1S	.031
	A030/2B	A22R	.031
	A030/3B	A23R	.015
	A027/2A	A8S	.015
	A027/3A	D8S	.015
	A027/3B	E2R	.031
	A027/2B	B21R	.25
	A014/3A	-	-
6	A020/3C	A1S	.015
	A020/5C	A1S	.031
	A020/2C	A1S	.031
	A020/1C	A1S	.015
	A020/4C	A1S	.015
	A018/3B	C2S	.125
	A007/2A	A1S	1.0
	A007/6A	B4S	.03
	A007/7A	A1S	.015
	A007/3B	A15S	.015
	A018/5B	C1S	4.0
7	A028/8A	D8S	-
	A025/5A	A1S	-
	A001/2A	A1S	4.0

Table 13 (cont.)

Cluster	strain	Biotype	Ketoconazole susceptibility
	A021/1A	A1S	-
	A052/5B	C26S	2.0
	A052/4B	A26S	1.0
	A052/1B	A14S	1.0
	A052/3B	A30S	1.0
	A052/2B	A19S	1.0
	A010/4A	B20S	.06
	A002/5B	A1R	-
	A002/4B	A13R	-
	A007/5B	A1S	.015
	A007/4B	A1S	.015
	A012/8B	B24S	.03
8	A003/4A	A1S	.25
	A003/15A	A1S	-
	A003/1A	B19S	.25
	A003/3A	A1S	.25
	A003/7A	A1S	.25
9	A083/4B	F4S	.031
	A083/5B	D14S	.031
	A083/3B	B16S	.015
	A027/4A	D1S	.06
10	A008/4B	A24S	.015
	A008/3B	A16S	.015
11	A003/3B	A1S	.015
	A003/1B	A17R	.015
	A003/2B	C13S	.015
	A004/1A	A14R	-
	A004/2A	B4S	-

Table 13 (cont.)

Cluster	strain	Biotype	Ketoconazole susceptibility
	A005/2A	A1S	.5
	A030/1B	G6R	.015
	A025/4B	A17S	.031
	A025/5B	A18S	.031
	A016/1B	A8S	.031
	A039/5B	C22R	4.0
12	A039/2B	E14R	4.0
	A039/1B	E21S	>4.0
	A039/3B	E29R	4.0
	A039/4B	C1R	4.0
	A059/3B	G2S	.031
	A059/2B	G2S	.031
	A059/4B	G2S	.062
13	A081/3B	B6S	.06
	A081/2B	A1S	.06
	A081/4B	A14S	.06
	A081/1B	A1S	.5
	A081/5B	A1S	.03
	A082/2B	A1S	.125
	A082/1B	A1S	.03
	A083/2B	B15S	.03
	A001/1B	A6S	.03
	A008/10A	A4S	.015
14	A013/4A	B1S	.25
	A013/2A	B1S	.03
	A018/2B	A22S	.5
Unrelated strain	A059/1B	C29S	.015
	A016/2B	A21S	.0075

Table 13 (cont.)

Cluster	strain	Biotype	Ketoconazole susceptibility
	A016/3B	A1S	.0075
	A016/4B	A8S	.0075
	A018/4A	-	-
	A018/1B	C2S	.25